Obermatt
See Similar Stocks →

Otsukas

TYO:4578 · JP3188220002
PharmaceuticalsX-Large

360

71
EV / EBIT64
Price / Owner Earnings78
Owner Earnings Yield92
Dividend Yield85
Price/Sales38
EV / Gross Profit87
Price/Book52
Return on Capital53
Cash Return on Capital57
Return on Equity49
EBIT Margin41
Gross Profitability71
Cash Conversion25
Accruals37
Owner Earnings Margin51
Sales growth33
Profit Growth45
Long-Term EPS Growth10
Owner Earnings Growth29
Reinvestment24
Price momentum97
Debt load81
Refinancing16
Debt Payback100
Liquidity86
Analyst ratings50
Opinion Changes50
Price Target Upside76
Market mood100
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Otsukas clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryJapan
IndustryPharmaceuticals
SizeX-Large
TypePublic Company
ExchangeTSE
Founded2008
Employees64
Websiteotsuka.com/jp
ISINJP3188220002
Last UpdateApr 2, 2026
Indices
Nikkei 225 (Japan)TOPIX 100 (Japan)
Themes
OphthalmologyHealth DiagnosticsNutraceuticalCardiovascularNeurologyPsychiatryOncologyBiotechnologyHealth CareManufacturingPharmaceutical

Description

Otsuka Holdings Co., Ltd. (Otsuka) operates in the healthcare industry, primarily focusing on the development, manufacturing, and marketing of innovative pharmaceutical and nutraceutical products. The company operates through diverse business segment…

Analysis

Bargain bin

Otsuka Holdings Co., Ltd. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.

On valuation, the picture is attractive. The owner-earnings multiple stands at 12.5×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is sturdy. The company scores 12/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
96
2023202420252026

All-time high

98

Feb 2024

All-time low

59

Jan 2023

Average rank

81

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
38
59
72
78
Price/Earnings
71
70
88
86
Price/Book
52
55
64
78
Dividend Yield
85
47
52
70
Value (overall)
76
46
48
79

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Otsukas with its peers
Kyongbo Pharmaceutical
KSC:214390
11
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Samil Pharmaceutical
KSC:000520
28
CountrySouth Korea
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Il Dong Pharmaceutical
KSC:249420
53
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
J. B. Chemicals & Pharmaceuticals
NSI:JBCHEPHARM
69
CountrySingapore
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
CSPC Pharmaceutical
HKG:1093
79
CountryChina
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Hansoh Pharmaceutical
HKG:3692
66
CountryHong Kong SAR China
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →